Network biomarkers and connectivity-based signatures may improve biotype stratification, enrich for likely responders, and reduce heterogeneity-driven signal dilution in both pharmacologic and device trials. Dynamic measures of network flexibility and switching may also serve as early markers of treatment trajectory. Programs that hard-wire these biomarkers into inclusion criteria, enrichment strategies, and key secondary endpoints will be better positioned for partner, payer, and regulatory conversations.